-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Fwv+GTJQQmoZ3UnEdRW78rhTQXjnXUoX3gPOYxZqnMJw7Damufmw1iuuLK6G8h6H
 f5lGdbATXOfDIQGVhK59Wg==

<SEC-DOCUMENT>0001144204-03-001684.txt : 20030414
<SEC-HEADER>0001144204-03-001684.hdr.sgml : 20030414
<ACCEPTANCE-DATETIME>20030414150644
ACCESSION NUMBER:		0001144204-03-001684
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20030221
FILED AS OF DATE:		20030414

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANHATTAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001001316
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				363898269
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-27282
		FILM NUMBER:		03648507

	BUSINESS ADDRESS:	
		STREET 1:		787 SEVENTH AVENUE
		STREET 2:		48TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		2125544555

	MAIL ADDRESS:	
		STREET 1:		787 SEVENTH AVENUE
		STREET 2:		48TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATLANTIC TECHNOLOGY VENTURES INC
		DATE OF NAME CHANGE:	20000330

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROSENWALD LINDSAY A MD
		CENTRAL INDEX KEY:			0000941841
		RELATIONSHIP:				OWNER

	FILING VALUES:
		FORM TYPE:		4/A

	BUSINESS ADDRESS:	
		STREET 1:		375 PARK AVE
		STREET 2:		SUITE 1501
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10152
		BUSINESS PHONE:		2128324366

	MAIL ADDRESS:	
		STREET 1:		375 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10152

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROSENWALD LINDSAY MD
		DATE OF NAME CHANGE:	19950316
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>form4.txt
<TEXT>
<PAGE>

                                                 OMB APPROVAL
                                                 OMB NUMBER  3235-0287
                                                 EXPIRES:  JANUARY 31, 2005
                                                 ESTIMATED AVERAGE BURDEN
                                                 HOURS PER RESPONSE  0.5

                     U.S. SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                     FORM 4

                  STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
       Section 17(a) of the Public Utility Holding Company Act of 1935 or
               Section 30(f) of the Investment Company Act of 1940

[X]  Check box if no longer subject to Section 16. Form 4 or Form 5 obligations
     may continue. See Instruction 1(b).

- --------------------------------------------------------------------------------
1.   Name and Address of Reporting Person

   Rosenwald, MD                    Lindsay                A.
- --------------------------------------------------------------------------------
   (Last)                           (First)             (Middle)

                        787 Seventh Avenue, 48/th/ Floor
- --------------------------------------------------------------------------------
                                    (Street)

   New York                            NY               10019
- --------------------------------------------------------------------------------
   (City)                           (State)              (Zip)


- --------------------------------------------------------------------------------
2.   Issuer Name and Ticker or Trading Symbol


Manhattan Pharmaceuticals, Inc. (f/k/a Atlantic Technology Ventures) ATLC.OB
- --------------------------------------------------------------------------------
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)



- --------------------------------------------------------------------------------
4.   Statement for Month/Day/Year

February 2003
- --------------------------------------------------------------------------------
5.   If Amendment, Date of Original (Month/Day/Year)

February 2003
- --------------------------------------------------------------------------------
6.   Relationship of Reporting Person to Issuer
     (Check all applicable)

     [ ]  Director                             [X]  10% Owner
     [ ]  Officer (give title below)           [ ]  Other (specify below)


- --------------------------------------------------------------------------------
7.   Individual or Joint/Group Filing (Check applicable line)

     [X]  Form filed by one Reporting Person
     [ ]  Form filed by more than one Reporting Person
- --------------------------------------------------------------------------------

<PAGE>

================================================================================
           Table I -- Non-Derivative Securities Acquired, Disposed of,
                             or Beneficially Owned
================================================================================

<TABLE>
<CAPTION>
                                                                                              5.             6.
                                                              4.                              Amount of      Owner-
                                                              Securities Acquired (A) or      Securities     ship
                                   2A.           3.           Disposed of (D)                 Beneficially   Form:    7.
                       2.          Deemed        Transaction  (Instr. 3, 4 and 5)             Owned Follow-  Direct   Nature of
                       Trans-      Execution     Code         ------------------------------- ing Reported   (D) or   Indirect
1.                     action      Date,         (Instr. 8)                   (A)             Transaction(s) Indirect Beneficial
Title of Security      Date        if  any       ------------     Amount      or     Price    (Instr. 3      (I)      Ownership
(Instr. 3)             (mm/dd/yy)  (mm/dd/yy)     Code     V                  (D)             and 4)         (Instr.4)(Instr. 4)
- -----------------------------------------------------------------------------------------------------------------------------------
<S>                    <C>         <C>           <C>     <C>      <C>         <C>    <C>      <C>            <C>       <C>

Common Stock            02/21/03                   J/1/           8,669,766    A         -     11,097,987     D
- -----------------------------------------------------------------------------------------------------------------------------------

- -----------------------------------------------------------------------------------------------------------------------------------

- -----------------------------------------------------------------------------------------------------------------------------------

===================================================================================================================================
</TABLE>


<PAGE>


FORM 4 (continued)

Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
         (e.g., puts, calls, warrants, options, convertible securities)

================================================================================
<TABLE>
<CAPTION>
                                                                                                           9.        10.
                                                                                                           Number    Owner-
                                                                                                           of        ship
                                                                                                           Deriv-    Form
              2.                                                                                           ative     of
              Conver-                           5.                              7.                         Secur-    Deriv-  11.
              sion                              Number of                       Title and Amount           ities     ative   Nature
              or               3A.              Derivative    6.                of Underlying     8.       Bene-     Secur-  of
              Exer-            Deemed   4.      Securities    Date              Securities        Price    ficially  ity:    In-
              cise     3.      Exe-     Trans-  Acquired (A)  Exercisable and   (Instr. 3 and 4)  of       Owned     Direct  direct
              Price    Trans-  cution   action  or Disposed   Expiration Date   ----------------  Deriv-   Following (D) or  Bene-
1.            of       action  Date,    Code    of(D)         (Month/Day/Year)            Amount  ative    Reported  In-     ficial
Title of      Deriv-   Date    if any   (Instr. (Instr. 3,    ----------------            or      Secur-   Trans-    direct  Owner-
Derivative    ative    (Month/ Month/   8)      4 and 5)      Date     Expira-            Number  ity      action    (I)     ship
Security      Secur-   Day/    Day/     ------  ------------  Exer-    tion               of      (Instr.  (Instr.   (Instr.(Instr.
(Instr. 3)    ity      Year)   Year)    Code V   (A)   (D)    cisable  Date     Title     Shares  5)       4)        4)      4)
- -----------------------------------------------------------------------------------------------------------------------------------
<S>           <C>      <C>     <C>      <C>     <C>    <C>    <C>      <C>      <C>       <C>     <C>      <C>       <C>      <C>

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- ----------------------------------------------------------------------------------------------------------------------------------

- -----------------------------------------------------------------------------------------------------------------------------------

===================================================================================================================================
</TABLE>

Explanation of Responses:

1    On February 21, 2003, Atlantic Technology Ventures, Inc. completed a merger
     with a private company, Manhattan Pharmaceuticals,  Inc. pursuant to which,
     Atlantic  issued 12.70967 shares of its Common Stock for each one (1) share
     of  Manhattan  Common  Stock  outstanding.  As a result of the Merger,  Dr.
     Rosenwald,  who is a stockholder of both  Manhattan and Atlantic,  received
     7,975,322 shares of Common Stock.

2    In connection with the Merger,  holders of certain Common Stock Warrants of
     Atlantic exchanged such warrants for shares of Common Stock on the basis of
     one share of Common Stock for every three shares of Common Stock underlying
     the  Warrants.  As a result,  Dr.  Rosenwald was issued  694,444  shares of
     Common Stock.


/S/                                                           April 7, 2003
- ----------------------------------------------            ----------------------
**Signature of Reporting Person                                   Date
Lindsay A. Rosenwald, MD


**     Intentional misstatements or omissions of facts constitute Federal
       Criminal Violations.


      See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note:  File three copies of this Form, one of which must be manually signed.
       If space provided is insufficient, see Instruction 6 for procedure.

                                        2
<PAGE>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
